{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:43:33Z","timestamp":1793051013009,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006436","name":"Silpakorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jgar.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:44:54Z","timestamp":1711529094000},"page":"219-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In vitro activity, pharmacodynamic profile and dose optimization of biapenem against NDM and OXA-48-like carbapenemase-producing Klebsiella pneumoniae: A multicentre study in Thailand"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-8591","authenticated-orcid":false,"given":"Worapong","family":"Nasomsong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirakhana","family":"Siangtrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnrada","family":"Nulsopapon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supanun","family":"Pungcharoenkijkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patcharapa","family":"Boonmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.03.010_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.010_bib0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-micro-090110-102911","article-title":"Epidemiological expansion, structural studies, and clinical challenges of new \u03b2-lactamases from gram-negative bacteria","volume":"65","author":"Bush","year":"2011","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.jgar.2024.03.010_bib0003","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fmicb.2013.00048","article-title":"\u201cStormy waters ahead\u201d: global emergence of carbapenemases","volume":"4","author":"Patel","year":"2013","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2024.03.010_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, epidemiology, and genetics of class D beta-lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13756-021-00950-7","article-title":"Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016\u20132018","volume":"10","author":"Paveenkittiporn","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"Suppl 7","key":"10.1016\/j.jgar.2024.03.010_bib0007","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2024.03.010_bib0009","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2024.03.010_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jac\/dks350","article-title":"Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001430","article-title":"In vitro effectiveness of biapenem against IMP-producing Enterobacteriaceae","volume":"70","author":"Gotoh","year":"2021","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2024.03.010_bib0012","unstructured":"Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; 30th ed. CLSI supplement M100. Available from: https:\/\/clsi.org. Accessed 20-12-2022."},{"key":"10.1016\/j.jgar.2024.03.010_bib0013","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 13.0. Accessed 20-6-2023."},{"key":"10.1016\/j.jgar.2024.03.010_bib0014","unstructured":"Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Update - CRE Toolkit 2015. Centers for Disease Control and Prevention. Available from: www.cdc.gov. Accessed 22-5-2020."},{"key":"10.1016\/j.jgar.2024.03.010_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.010_bib0016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.010_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s101560050041","article-title":"Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released","volume":"5","author":"Saito","year":"1999","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0018","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2010.01.002","article-title":"In vitro activity of biapenem against Burkholderia pseudomallei","volume":"35","author":"Thamlikitkul","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.03.010_bib0019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clinmicnews.2013.06.001","article-title":"Verification of antimicrobial susceptibility testing methods: a practical approach","volume":"35","author":"Patel","year":"2013","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.jgar.2024.03.010_bib0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000152459","article-title":"Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy","volume":"54","author":"Ikawa","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jgar.2024.03.010_bib0021","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2024.03.010_bib0022","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2024.03.010_bib0023","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1128\/AAC.01397-09","article-title":"In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates","volume":"54","author":"Ishii","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2024.03.010_bib0025","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.010_bib0026","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1128\/AAC.00497-11","article-title":"Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment","volume":"55","author":"Ikawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0027","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.01578-08","article-title":"Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions","volume":"53","author":"Kikuchi","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0028","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.rmed.2005.05.009","article-title":"Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy","volume":"100","author":"Niwa","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jgar.2024.03.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02612-20","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of biapenem in healthy adult subjects","volume":"65","author":"Griffith","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.010_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijantimicag.2017.07.005","article-title":"Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"51","author":"Hang","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.03.010_bib0031","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2015.12.018","article-title":"Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation","volume":"47","author":"Dong","year":"2016","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:27:14Z","timestamp":1718681234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"alternative-id":["S2213716524000596"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity, pharmacodynamic profile and dose optimization of biapenem against NDM and OXA-48-like carbapenemase-producing Klebsiella pneumoniae: A multicentre study in Thailand","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}